2012 Tuberous Sclerosis Complex Clinical Trial Award Program
Page 2

With this, the funding agency requires the proposals to be submitted under this program to focus on the following areas:

a) The studies of the pathogenesis, disease severity prediction and diversity of symptoms that affects a patient's cognition, behavior, sleep, renal and pulmonary functions, along with the signs and symptoms of epilepsy and autism

b) The studies regarding the impact of TSC manifestations over the lifespan of a patient

c) The determination of novel strategies for the management and prevention of TSC manifestations including early therapeutic approaches

d) The deep comprehension of the cellular and molecular mechanisms of TSC developmental stages in mammalian and non-mammalian systems

e) Genetic, epigenetic, and non-genetic modifiers of TSC

f) The identification of biomarkers for early detection, prognosis, and prediction of TSC treatment outcomes.

To support this activities covered under this initiative, the Department of Defense is willing to administer funds in the amount of $1,600,000 per year, for a maximum project period of up to 4 years.

Assistant Professors or Lead Professors at Accredited Colleges and Universities are encouraged to submit an application under the 2012 Tuberous Sclerosis Complex Clinical Trial Award Program.

2012 Tuberous Sclerosis Complex Clinical Trial Award Program
  Back to Page 1

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on community grants and health grants.

Additional Resources

category - Health Grants

Excellence in Hemoglobinopathies Research Award Program
The National Institutes of Health has formed a collaboration with the National Heart, Lung, and Blood Institute (NHLBI) in an effort to establish the Excellence in Hemoglobinopathies Research Award Program wherein both agencies have agreed to financially support the creation of studies that could potentially improve high-impact multi-disciplinary basic and translational research studies in the hemoglobinopathies.

---

Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program
In this capacity, the Food and Drug Administration has recently established the Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program in an attempt to study the effects of various physicochemical properties of ophthalmic suspensions and emulsions on ocular bioavailability.

---

The Collaborative Islet Transplantation Registry Program
The National Institutes of Health has formed a partnership with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in order to establish the The Collaborative Islet Transplantation Registry Program wherein both agencies seek to invite applications that intend to continue initiatives started through the Collaborative Islet Transplantation Registry (CITR).

---

Minority-Based Community Clinical Oncology Program Groups
In line with this mission, the National Institutes of Health has recently collaborated with the National Cancer Institute (NCI) in an attempt to establish the Minority-Based Community Clinical Oncology Program Groups (MBCCOP).

---